Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

69.70
-2.8800-3.97%
Post-market: 69.700.00000.00%16:37 EDT
Volume:1.23M
Turnover:85.87M
Market Cap:13.51B
PE:-18.44
High:73.03
Open:72.33
Low:69.44
Close:72.58
52wk High:84.94
52wk Low:28.33
Shares:193.86M
Float Shares:151.20M
Volume Ratio:0.71
T/O Rate:0.81%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.7800
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-33.83%
PB:-6.48
PE(LYR):-18.41

Loading ...

BridgeBio Pharma Inc : JP Morgan Adds Stock to Its US Analyst Focus List

THOMSON REUTERS
·
Mar 10

BridgeBio Pharma Director Andrea Ellis Disposes of Common Shares

Reuters
·
Mar 07

BridgeBio Oncology Therapeutics Inc reports results for the quarter ended December 31 - Earnings Summary

Reuters
·
Mar 06

BridgeBio Pharma to Present Additional Phase 3 FORTIFY BBP-418 Interim Data at MDA Clinical and Scientific Conference

Reuters
·
Mar 04

BridgeBio Pharma Director Hannah Valantine Disposes of Common Shares

Reuters
·
Mar 04

A Look At BridgeBio Pharma (BBIO) Valuation After Phase 3 Wins And Attruby Commercial Momentum

Simply Wall St.
·
Mar 03

Ascendis wins U.S. approval for therapy for children with dwarfism

Reuters
·
Feb 28

BridgeBio Oncology Therapeutics Inc expected to post a loss of 52 cents a share - Earnings Preview

Reuters
·
Feb 28

BridgeBio Pharma Chief Accounting Officer Maricel Apuli Disposes of Common Shares

Reuters
·
Feb 28

Stock Track | BridgeBio Pharma Plummets 5.01% Intraday Amid Mixed Analyst Target Price Revisions

Stock Track
·
Feb 26

BridgeBio Pharma (BBIO) Gets a Buy from Jefferies

TIPRANKS
·
Feb 25

BridgeBio Pharma Is Maintained at Overweight by Morgan Stanley

Dow Jones
·
Feb 25

BridgeBio price target raised to $95 from $86 at Truist

TIPRANKS
·
Feb 25

BridgeBio Pharma Is Maintained at Outperform by Evercore ISI Group

Dow Jones
·
Feb 25

BridgeBio Pharma, Inc. : Oppenheimer Cuts Target Price to $81 From $83

THOMSON REUTERS
·
Feb 25

BridgeBio price target raised to $125 from $100 at Evercore ISI

TIPRANKS
·
Feb 25

Stock Track | BridgeBio Pharma Soars 5.40% in Pre-Market on Multiple Analyst Price Target Hikes

Stock Track
·
Feb 25

Morgan Stanley Lifts Price Target on BridgeBio Pharma to $98 From $96, Keeps Overweight Rating

MT Newswires Live
·
Feb 25

Barclays Sticks to Its Buy Rating for BridgeBio Pharma (BBIO)

TIPRANKS
·
Feb 25

U.S. RESEARCH ROUNDUP-Chevron, GoDaddy, HP

Reuters
·
Feb 25